modelOxantel

Extends from Pharmacolibrary.Drugs.ATC.P.P02CC02.

Information

name:Oxantel
ATC code:P02CC02
route:oral
compartments:1
dosage:500mg
volume of distribution:2.0L
clearance:0.1L/kg/h
other parameters in model implementation

Oxantel is an anthelmintic agent used primarily to treat infections caused by whipworm (Trichuris trichiura) and, in combination with pyrantel, for other soil-transmitted helminthiases. It acts as a nicotinic acetylcholine receptor agonist, causing spastic paralysis in susceptible nematode worms. While oxantel is included in WHO guidelines for deworming, it is currently not widely approved as a standalone medicine in many countries, but combination products are in use.

Pharmacokinetics

No published human pharmacokinetic studies were found for oxantel. Pharmacokinetic parameters reported here are estimated based on available animal studies (such as in rats and dogs) and general physicochemical drug properties. Dose and parameters are typical for deworming use in combination with pyrantel in adults.

References

  1. Palmeirim, MS, et al., & Keiser, J (2021). Preclinical and Clinical Characteristics of the Trichuricidal Drug Oxantel Pamoate and Clinical Development Plans: A Review. Drugs 81(8) 907–921. DOI:10.1007/s40265-021-01505-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33929716

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)